Overall benefits provided by orthopedic surgical intervention in patients with rheumatoid arthritis

Ishikawa, Hajime; Abe, Asami; Kojima, Toshihisa; Kojima, Masayo; Ishiguro, Naoki; Nomura, Yumi; Otani, Hiroshi; Hasegawa, Eietsu; Kobayashi, Daisuke; Ito, Satoshi; Nakazono, Kiyoshi; Murasawa, Akira

doi:10.1080/14397595.2018.1457468

Cited by 15 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirty‐one studies reported utility scores of RA patients 22‐24,34‐42,45,47‐63,65 . The pooled mean EQ‐5D score was 0.66 (95% CI 0.63‐0.69) with high heterogeneity I 2 = 99.65% (Figure 2A).…”

Section: Resultsmentioning

confidence: 99%

“…Eleven studies did not mention the EQ-5D 3L/5L version. 22,35,38,42,44,45,[51][52][53][54]59 In 15 out of 37 studies, RA patients were diagnosed using the American College of Rheumatology (ACR) 1987 criteria 68 and 22 studies did not mention the diagnosis criteria for RA. The median RA disease duration available from 26 studies was 9.4 (7.2-9.9) years.…”

Section: Re Sultsmentioning

confidence: 99%

“…Thirty-one studies reported utility scores of RA patie nts. [22][23][24][34][35][36][37][38][39][40][41][42]45,[47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63]65 The pooled mean EQ-5D score was 0.66 (95% CI 0.63-0.69) with high heterogeneity I 2 = 99.65% (Figure 2A).…”

Section: Overall Pooling Of Eq-5dmentioning

confidence: 99%

See 2 more Smart Citations

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

2021

View full text Add to dashboard Cite

Introduction Region‐specific health‐related quality of life (HRQoL) scores or utility values are representative and pivotal for economic evaluations as they are influenced by the value judgment of the local population. This study systematically reviewed and pooled EuroQoL‐5 Dimension (EQ‐5D) utility scores of rheumatoid arthritis (RA) across primary studies from Asia. Methods Studies reporting EQ‐5D utility scores among adult RA patients from Asian countries were systematically searched in PubMed‐Medline, Scopus and Embase since inception through February 2020. Selected studies were systematically reviewed and study quality assessment was performed. Meta‐analysis was performed using a random‐effect model with subgroup and meta‐regression analysis to explore heterogeneity. Results Among 1391 searched articles, 37 studies with 31 983 participants were systematically reviewed and meta‐analysis was conducted among 31 studies. The pooled EQ‐5D scores and EQ‐5D visual analog score were 0.66 (95% CI 0.63‐0.69, I2 = 99.65%) and 61.21 (50.73‐71.69, I2 = 99.56%) respectively with high heterogeneity. For RA patients with no, low, moderate and high disease activity based on Disease Activity Score (DAS)‐28, the pooled EQ‐5D scores were 0.78 (0.65‐0.90), 0.73 (0.65‐0.80), 0.53 (0.32‐ 0.74), and 0.47 (0.32‐0.62), respectively. On meta‐regression, age of patients (P < .05) was positively associated and use of glucocorticoids (P < .05) was inversely associated with utility values. Conclusion Lower EQ‐5D scores were associated with severe disease activity, increasing age and female gender among RA patients. The study provides pooled EQ‐5D scores for RA patients that are useful inputs for cost‐utility studies in Asia.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Re Sultsmentioning

confidence: 99%

See 1 more Smart Citation

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

2021

View full text Add to dashboard Cite

show abstract

“…The RA status was evaluated at 0 and 52 weeks and at the final follow-up based on the following: DAS28-ESR, MTX dose, and PSL dose. The grip power and J-HAQ were also assessed to determine the improvement in the ADL (26). The average grip power of both hands was measured using a mercury dynamometer, which was able to measure from 0 to 300 mmHg (28.9 kg).…”

Section: Methodsmentioning

confidence: 99%

“…Previous reports on the prevalence of sarcopenia have varied; for example, a meta-analysis showed that the prevalence of sarcopenia in patients with RA was 15-32% (25), and Torii et al reported a prevalence of 37.1% in Japanese patients (23). In addition, Ishikawa et al reported that the handgrip power in Japanese patients with RA reflects the level of independence in activity of daily living (ADL), and the cut-off value for independent ADL was 136.5 mmHg (11.8 kgw) for women and 152.5 mmHg (13.5 kgw) for men (26,27). Only one report has described an improvement in the grip power following the use of bDMARDs, with the use of TNF inhibitors for more than one year being shown to improve the grip power in patients with RA (28).…”

Section: Introductionmentioning

confidence: 99%

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objective To evaluate the effectiveness and drug retention rate of golimumab (GLM) for long-term use in daily practice for patients with rheumatoid arthritis (RA). Methods Patients with RA who started GLM therapy with a minimum follow-up period of 52 weeks were included. The patients were divided into a biologic-naïve group and switch group. The disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR) (DAS28-ESR), grip power, and Japanese version of the health assessment questionnaire (J-HAQ) score were assessed. In addition, the treatment continuation rate was evaluated at the final follow-up. Patients Sixty-five patients (58 women and 7 men; median [range] age, 69 [61-74] years; median [range] disease duration, 9 [5-16] years) were included. Twenty-eight patients were biologic-naïve (naïve group), and 37 were switched to biologics (switch group). Results The median (range) follow-up period was 134 (58-162) weeks. The DAS28-ESR improved from a median (range) of 4.31 (3.52-5.25) to 2.65 (2.28-3.77) in the naïve group and from 4.27 (3.19-4.89) to 2.89 (2.49-3.88) in the switch group. The grip power improved in both groups (p<0.01); however, the J-HAQ score showed no marked improvement in either group. The continuation rates were 22/28 (78.6%) in the naïve group, and 26/37 (70.3%) in the switch group at the final follow-up. Conclusion We herein report for the first time that the long-term use of GLM improves the grip power. Improving the grip power may help prevent sarcopenia and frailty in the future. Given the efficacy and high continuation rate, we suggest that GLM would be a well-tolerated treatment option for RA.

show abstract

Erkrankungen der Synovialmembran des Kniegelenkes: Entzündlich-rheumatische Erkrankungen

Gaulke¹

2023

Orthopädie Und Unfallchirurgie

View full text Add to dashboard Cite

Overall benefits provided by orthopedic surgical intervention in patients with rheumatoid arthritis

Abstract: Overall benefits were provided by orthopedic surgical intervention generally in patients with RA.

Cited by 15 publications

References 23 publications

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis

Erkrankungen der Synovialmembran des Kniegelenkes: Entzündlich-rheumatische Erkrankungen

Contact Info

Product

Resources

About